The United States market has shown strong performance, with a 1.7% increase over the last week and a 25% rise over the past year. Amidst these positive trends, penny stocks—typically representing smaller or newer companies—remain an intriguing option for investors seeking growth at lower price points. Although considered somewhat outdated, the term still captures opportunities in this investment area, especially when focusing on companies with robust financials and clear growth potential.

Let's review some notable picks from our screened stocks.

Organogenesis Holdings (ORGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $313.97 million.

Operations: The company's revenue is derived entirely from its regenerative medicine segment, totaling $514.70 million.

Market Cap: $313.97M

Organogenesis Holdings Inc., a regenerative medicine company, faces challenges as it remains unprofitable with increasing losses over the past five years. Despite reporting US$37.23 million in revenue for Q1 2026, a significant decline from the previous year, its short-term assets of US$268.5 million exceed liabilities, providing some stability. The seasoned management team and board offer experience to navigate market headwinds. The recent completion of a Biologics License Application for ReNu and positive trial results for PuraPly®AM highlight potential product advancements; however, financial performance pressures persist amid declining sales forecasts for 2026.

Outdoor Holding (POWW)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Outdoor Holding Company operates an online marketplace business and has a market cap of approximately $251 million.

Operations: The company generates revenue of $46.02 million from its online marketplace segment.

Market Cap: $251M

Outdoor Holding Company, with a market cap of US$251 million, generates US$46.02 million in revenue from its online marketplace segment but remains unprofitable with increasing losses over the past five years. The company maintains a strong balance sheet, as short-term assets of US$82.5 million exceed both short- and long-term liabilities, and it holds more cash than total debt. Recent strategic moves include appointing Erich Buerger as Director of AI Strategy to enhance platform performance through AI initiatives. Despite these developments, profitability is not expected within the next three years according to analyst forecasts.

SES AI (SES)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SES AI Corporation focuses on developing and producing AI-enhanced lithium metal and lithium-ion rechargeable battery technologies for various applications, including electric vehicles and drones, with a market cap of approximately $395.13 million.

Operations: The company generates revenue primarily from its Batteries / Battery Systems segment, amounting to $21.92 million.

Market Cap: $395.13M

SES AI Corporation, with a market cap of approximately US$395.13 million, focuses on AI-enhanced battery technologies and reported Q1 2026 sales of US$6.71 million but remains unprofitable with increasing losses over the past five years. The company has a solid cash position, covering both short- and long-term liabilities comfortably, and its debt level is minimal compared to cash reserves. Despite revenue growth forecasts of 38.32% annually, challenges include legal issues from a class action lawsuit alleging misleading business prospects and overstated revenues. SES recently appointed Yi Liu as CFO amid ongoing strategic adjustments to stabilize operations and improve financial performance.

Make It Happen

• Click here to access our complete index of 336 US Penny Stocks.
• Interested In Other Possibilities? These 25 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.